We use cookies to help provide you with the best possible online experience. By using this site, you agree that we may store and access cookies on your device. You can find out more about how to set your own preferences here.
Accept cookies

Claudio Pozzoli promoted to CSO

Lugano, January 1st 2017, January 01 2017

Following a corporate restructuring and the streamlining of operations at Cerbios-Pharma SA (from now on CERBIOS), we are proud to announce the promotion of Claudio Pozzoli to the position of Chief Scientific Officer (CSO).

Claudio Pozzoli will lead the newly created R&D Division, which includes both divisions: Chemical and Biological.

The two teams that were directly reporting to the CEO will now report to him directly. In his new role he will be responsible for all development activities, from our partners’ Technology Transfer to Internal Scale-up Transfer as well as commercial production troubleshooting.

Claudio Pozzoli will report directly to Gabriel Haering (CEO) and will  be part of the company’s top management team.

“This structural change was required because of company growth and the increasing complexity of the new projects under evaluation and implementation that need both chemical and biological competence under one unified direction.” says Gabriel Haering, CEO.

“Furthermore he will supervise and coordinate the complex and challenging activities related to the development and manufacturing of Antibody Drug Conjugates (ADCs) where the combination of both chemical and biological expertise are required.

Appointing Claudio Pozzoli as CSO is also part of the CERBIOS’ organizational strategy, initiated some years ago, that integrates all our activities into a leaner structure, creating value for our partners”.

He joined CERBIOS on October 1st, 2015 as Director R&D Chemical Division.

For more details on his career see also his profile at the following link.

About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
Download file (File size - 0.19)
[[ getItemTitle(currentIndex) ]]